Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPKINLY Subcutaneous Injection Post-marketing All-case Surveillance in Relapsed or Refractory B-cell Lymphomas
jRCT2031230525Active, not recruiting
- Sponsor
- Genmab
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Genmab. Primary endpoint: Incidence of CRS, ICANS, infections, cytopenia, tumor lysis syndrome, and progressive multifocal leukoencephalopathy. Started Dec 2023; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2031230525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230525.